NCT07017725: A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 75 planned
- Started
- 3 Jan 2025
- Primary completion
- 1 Jun 2026
- Arms
- Part B (Randomized Dose Exploration) high-dose cohort, Part B (Randomized Dose Exploration) intermediate-dose cohort, Part B (Randomized Dose Exploration) low-dose cohort, Part A (Dose Escalation) Cohort 1- 30 mg/30 mg, Part A (Dose Escalation) Cohort 1- 30 mg/150 mg, Part A (Dose Escalation) Cohort 1- 150 mg/300 mg, Part A (Dose Escalation) Cohort 1- 150 mg/600 mg, Part A (Dose Escalation) Cohort 1- 150 mg/900 mg
- Results
- None posted
- 3 Jan 2025: Trial started
- 12 Jun 2025: Trial registered